Research programme: aurora kinase inhibitors - SuperGen

Drug Profile

Research programme: aurora kinase inhibitors - SuperGen

Alternative Names: MP 529 series; MP-529

Latest Information Update: 26 Sep 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Aurora kinase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Apr 2008 Pharmacokinetics and adverse events data from a Preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
  • 06 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the Cancer pharmacodynamics section
  • 05 Apr 2006 Montigen has been acquired and merged into SuperGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top